These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8902431)

  • 1. Pharmacokinetics of levofloxacin in comparison to the racemic mixture of ofloxacin in man.
    Verho M; Malerczyk V; Damm D; Lehr KH
    Drug Metabol Drug Interact; 1996; 13(1):57-67. PubMed ID: 8902431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.
    Chien SC; Wong FA; Fowler CL; Callery-D'Amico SV; Williams RR; Nayak R; Chow AT
    Antimicrob Agents Chemother; 1998 Apr; 42(4):885-8. PubMed ID: 9559801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical pharmacokinetics of levofloxacin.
    Fish DN; Chow AT
    Clin Pharmacokinet; 1997 Feb; 32(2):101-19. PubMed ID: 9068926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses.
    Chien SC; Rogge MC; Gisclon LG; Curtin C; Wong F; Natarajan J; Williams RR; Fowler CL; Cheung WK; Chow AT
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2256-60. PubMed ID: 9333057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects.
    Lee LJ; Hafkin B; Lee ID; Hoh J; Dix R
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2196-200. PubMed ID: 9333047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose linearity and other pharmacokinetics of ofloxacin: a new, broad-spectrum antimicrobial agent.
    Verho M; Malerczyk V; Dagrosa E; Korn A
    Pharmatherapeutica; 1985; 4(6):376-82. PubMed ID: 3866256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine.
    Chien SC; Chow AT; Rogge MC; Williams RR; Hendrix CW
    Antimicrob Agents Chemother; 1997 Aug; 41(8):1765-9. PubMed ID: 9257757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection.
    Goodwin SD; Gallis HA; Chow AT; Wong FA; Flor SC; Bartlett JA
    Antimicrob Agents Chemother; 1994 Apr; 38(4):799-804. PubMed ID: 8031049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tear concentration and safety of levofloxacin ophthalmic solution 1.5% compared with ofloxacin ophthalmic solution 0.3% after topical administration in healthy adult volunteers.
    Walters T; Rinehart M; Krebs W; Holdbrook M
    Cornea; 2010 Mar; 29(3):263-8. PubMed ID: 20098307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative bioavailability of ofloxacin tablets in comparison to oral solution.
    Malerczyk V; Verho M; Korn A; Rangoonwala R
    Curr Med Res Opin; 1987; 10(8):514-20. PubMed ID: 3479296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers.
    Chow AT; Fowler C; Williams RR; Morgan N; Kaminski S; Natarajan J
    Antimicrob Agents Chemother; 2001 Jul; 45(7):2122-5. PubMed ID: 11408234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple-dose pharmacokinetics of ofloxacin, a new broad-spectrum antimicrobial agent.
    Dagrosa EE; Verho M; Malerczyk V; de Looze S; Hajdú P; Toyodera K
    Clin Ther; 1986; 8(6):632-45. PubMed ID: 3466701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit.
    Rebuck JA; Fish DN; Abraham E
    Pharmacotherapy; 2002 Oct; 22(10):1216-25. PubMed ID: 12389872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of levofloxacin in healthy Thai male volunteers.
    Chulavatnatol S; Chindavijak B; Vibhagool A; Wananukul W; Sriapha C; Sirisangtragul C
    J Med Assoc Thai; 1999 Nov; 82(11):1127-35. PubMed ID: 10659548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tear concentrations of levofloxacin following topical administration of a single dose of 0.5% levofloxacin ophthalmic solution in healthy volunteers.
    Raizman MB; Rubin JM; Graves AL; Rinehart M
    Clin Ther; 2002 Sep; 24(9):1439-50. PubMed ID: 12380635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of multiple intravenous instillation of levofloxacin in Chinese healthy subjects.
    Zhang L; Li JT; Lu Y; Li MN; Zhang YL; Liu Y; Li TY; Zhang JW
    Acta Pharmacol Sin; 2002 Apr; 23(4):381-4. PubMed ID: 11931699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose related pharmacokinetics of ofloxacin in healthy volunteers.
    Immanuel C; Hemanthkumar AK; Gurumurthy P; Venkatesan P
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):1017-22. PubMed ID: 12475149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of food on the pharmacokinetics of ofloxacin.
    Verho M; Malerczyk V; Dagrosa E; Korn A
    Curr Med Res Opin; 1986; 10(3):166-71. PubMed ID: 3460737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and safety of high-dose and extended-interval regimens of levofloxacin in human immunodeficiency virus-infected patients.
    Piscitelli SC; Spooner K; Baird B; Chow AT; Fowler CL; Williams RR; Natarajan J; Masur H; Walker RE
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2323-7. PubMed ID: 10471591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of ofloxacin enantiomers after intravenous administration for antibiotic prophylaxis in biliary surgery.
    Gascón AR; Campo E; Hernández RM; Calvo B; Errasti J; Pedraz Muñoz JL
    J Clin Pharmacol; 2000 Aug; 40(8):869-74. PubMed ID: 10934671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.